Core Viewpoint - The article highlights the significant growth and strategic initiatives of Guolian Minsheng Securities in supporting private technology innovation enterprises, particularly in the Yangtze River Delta region, showcasing successful case studies like Haofan Bio and Haoyuan Pharmaceutical [5][6][17]. Group 1: Financial Performance - Guolian Minsheng's investment banking business reported a net income of 688 million yuan for the first three quarters of 2025, marking a year-on-year increase of 160.77% [5]. - The company's bond underwriting scale reached 48.38 billion yuan, reflecting a year-on-year growth of 147.5%, significantly outpacing industry growth rates [5]. Group 2: Company Initiatives - Haofan Bio is expanding its production capacity by 3 to 4 times with a new 230-acre facility set to be operational by June 2026 [5]. - Haoyuan Pharmaceutical is establishing five high-activity GMP production lines at its research center in Ma'anshan, aiming to accelerate the development of new molecular drugs [5][6]. Group 3: Industry Strategy - Guolian Minsheng emphasizes a strategy of "deep regional engagement + industry specialization," which has proven effective in addressing the challenges faced by private technology innovation enterprises [6][8]. - The firm has established 12 industry groups within its investment banking department to enhance its research capabilities and provide specialized services [8]. Group 4: Market Positioning - The article notes that Haofan Bio and Haoyuan Pharmaceutical are leaders in their respective fields, with a focus on long-term growth and innovation [11][17]. - Guolian Minsheng's investment banking team has successfully assisted Haoyuan Pharmaceutical in completing its initial public offering (IPO) and subsequent strategic initiatives, including mergers and acquisitions [12]. Group 5: Regional Focus - The Yangtze River Delta region is highlighted as a key area for technology innovation, with Guolian Minsheng actively providing financial services tailored to local industry needs [14][16]. - The firm aims to support high-quality development in the region by focusing on sectors such as biomedicine, semiconductors, artificial intelligence, and new energy [16][17].

证券日报网讯 12月10日，昊帆生物在互动平台回答投资者提问时表示，公司主要产品为多肽合成试 剂、通用型分子砌块等化学试剂，主要用于酰胺键的化学合成。公司经营会受到下游需求波动、价格波 动、行业竞争、产能布局等多方面因素影响，请投资者注意相关风险，理性判断。 （文章来源：证券日报） ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：司美格鲁肽核心专利将于明年三月份到期，对公司经 营是否会有积极影响？ 昊帆生物（301393.SZ）12月10日在投资者互动平台表示，公司主要产品为多肽合成试剂、通用型分子 砌块等化学试剂，主要用于酰胺键的化学合成。公司经营会受到下游需求波动、价格波动、行业竞争、 产能布局等多方面因素影响，请投资者注意相关风险，理性判断。 ...

（记者 王晓波） 昊帆生物（301393.SZ）12月10日在投资者互动平台表示，根据项目备案通知书，淮安昊帆新建年产 5130吨多肽合成试剂项目（一期）规划的生产规模为：年产缩合试剂2500吨、保护试剂800吨、绿色N 氨基化试剂100吨、手性消旋抑制试剂400吨、蛋白质试剂20吨、缩合活化助剂600吨、核苷酸试剂400 吨、多肽合成交联剂20吨、保护氨基酸290吨。本项目尚在建设中，未来可能根据市场需求变化、客户 开拓情况及公司战略调整进行动态优化，具有不确定性，请投资者注意相关风险。 每经AI快讯，有投资者在投资者互动平台提问：淮安昊帆生产基地建设项目，规划产品34种，设计产 能为每年5130吨。2026年先建设5个车间生产。请问淮安昊帆生产的产品分别是哪些？产能各自是多 少？ ...

每经AI快讯，有投资者在投资者互动平台提问：司美格鲁肽核心专利将于明年三月份到期，对公司经 营是否会有积极影响？ （记者 王晓波） 昊帆生物（301393.SZ）12月10日在投资者互动平台表示，公司主要产品为多肽合成试剂、通用型分子 砌块等化学试剂，主要用于酰胺键的化学合成。公司经营会受到下游需求波动、价格波动、行业竞争、 产能布局等多方面因素影响，请投资者注意相关风险，理性判断。 ...

Core Viewpoint - Haofan Bio (301393) reported that its overseas sales revenue for 2024 is projected to account for 22.13% from Asia, 10.04% from Europe, and 4.09% from America of the total operating revenue [1] Group 1: Company Overview - The main products of the company are specialty chemical raw materials primarily based on peptide synthesis reagents, positioned upstream in the pharmaceutical industry chain [1] - The company offers a wide range of products and serves thousands of customers annually, demonstrating strong risk resistance capabilities [1] Group 2: Market Expansion - The company established a wholly-owned subsidiary in Germany in January 2025, targeting CDMO and formulation clients in the European market to further expand its business in Europe [1]

（文章来源：证券日报） 证券日报网讯昊帆生物11月18日在互动平台回答投资者提问时表示，公司服务众多医药研发与生产企 业，为下游客户提供以多肽合成试剂和分子砌块为主的各类特色化学试剂。 ...

Core Insights - The peptide synthesis reagent industry is experiencing rapid growth driven by the expanding global peptide drug market, which is projected to reach $110.7 billion in 2024 and $121.7 billion in 2025, with the U.S. holding a dominant share and China showing significant potential [1][6][8] - China's peptide drug market is expected to grow from approximately 55.44 billion yuan in 2024 to 61.2 billion yuan in 2025, providing a solid demand foundation for upstream reagent industries [1][8] - The Chinese peptide synthesis reagent market is projected to grow from about 2.44 billion yuan in 2024 to 2.68 billion yuan in 2025, with strong growth in the ion-type condensation reagent segment [1][9] Industry Overview - Peptide synthesis reagents are specialized chemical agents that facilitate the formation of peptide bonds between amino acids, protect active groups, and suppress side reactions, making them essential in peptide drug development and biomedical research [2][3] - The industry is transitioning from traditional fermentation and extraction methods to chemical synthesis and gene recombination methods, which now dominate the market [5][6] Market Dynamics - The global peptide drug market is expanding due to advancements in synthesis and modification technologies, with a notable increase in demand for innovative therapies targeting chronic diseases [6][8] - In China, the rapid development of the peptide drug market is supported by policy initiatives, clinical demand, and technological advancements, with a projected market size of approximately 554.4 billion yuan in 2024 [8][9] Competitive Landscape - The Chinese peptide synthesis reagent industry features a fragmented competitive landscape with a mix of specialized and comprehensive companies, where most focus on specific types of reagents [10][11] - Leading companies like Haofan Bio are establishing a strong position by offering a full range of peptide synthesis reagents, while other firms focus on niche markets [11][12] Development Trends - The industry is moving towards technological innovation, with a focus on green and efficient synthesis methods, and a shift from single-function to multifunctional reagents [12][13] - Domestic companies are increasingly penetrating high-end markets, breaking the monopoly of international brands in high-purity and low racemization reagents [13][14] - The competitive landscape is evolving from fragmented product competition to an ecosystem of collaborative competition, with leading firms building comprehensive product matrices and enhancing vertical integration [14]

Core Viewpoint - Haofan Bio, a leading company in the peptide synthesis reagent sector, was established in December 2003 and went public on July 12, 2023, in Shenzhen, with its headquarters in Suzhou, Jiangsu Province [1] Group 1: Business Overview - Haofan Bio specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks, with a focus on peptide drugs, innovative drugs, and biopharmaceuticals [1] - The company has a differentiated advantage in technology and customer resources [1] Group 2: Financial Performance - In Q3 2025, Haofan Bio reported revenue of 435 million yuan, ranking 24th among 34 companies in the industry, while the industry leader, Changchun High-tech, had revenue of 9.807 billion yuan [2] - The net profit for the same period was approximately 99.24 million yuan, placing the company 16th in the industry, with the top performer, Tonghua Dongbao, reporting a net profit of 1.188 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Haofan Bio's debt-to-asset ratio was 7.86%, significantly lower than the industry average of 26.88%, indicating strong solvency [3] - The company's gross profit margin was 38.75%, which is below the industry average of 70.17%, suggesting room for improvement in profitability [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 12.14% to 10,000, while the average number of circulating A-shares held per shareholder increased by 19.09% to 4,200.4 [5] - The fifth largest circulating shareholder, Huatai-PB Health Mixed Fund, increased its holdings by 26,430 shares [5] Group 5: Future Outlook - The company is expected to maintain steady growth, with projected net profits of 166 million, 208 million, and 268 million yuan for 2025 to 2027, respectively, and corresponding EPS of 1.54, 1.93, and 2.48 yuan [5] - Haofan Bio has established a presence in over 1,900 pharmaceutical-related enterprises globally and is actively expanding into the European market [5] - The company is enhancing its production capacity through self-built facilities and acquisitions, with ongoing projects in Anhui and Huai'an expected to resolve capacity issues by mid-2026 [5]

Core Viewpoint - Haofan Bio, a leader in the domestic peptide synthesis reagent sector, has shown significant growth and is well-positioned to capitalize on the expanding global biopharmaceutical market, particularly in peptide drugs [2][6]. Financial Performance - In the first half of 2025, Haofan Bio reported a revenue of 270 million yuan, representing a year-on-year growth of 20.1%, and a net profit attributable to shareholders of 75.88 million yuan, up 15.3% year-on-year [2]. R&D and Capacity Upgrades - Following its listing on the ChiNext board in 2023, Haofan Bio has accelerated its dual upgrades in R&D and production capacity, with a 30% increase in R&D personnel and the construction of three production bases to alleviate capacity constraints [3][6]. - The company has also established a new R&D building and introduced advanced research and testing equipment [3]. Technology and Product Development - Haofan Bio has developed a comprehensive range of peptide synthesis reagents, from the first to the fourth generation, becoming one of the few global manufacturers to cover the entire series [4][5]. - The company is actively expanding its product system to include general molecular building blocks and pharmaceutical reagents for liposomes and lipid nanoparticles, with over 120 types of these reagents in small-scale research and some entering small batch production [5]. Market Opportunities and Challenges - The global peptide drug market is expected to exceed $100 billion by 2027, presenting significant opportunities for Haofan Bio, although capacity shortages remain a critical issue [6]. - The company plans to address this by acquiring Foster Pharmaceutical for 160 million yuan, which will provide additional production capacity and facilitate the transition of new products from small-scale trials to mass production [6]. Strategic Focus - Haofan Bio emphasizes a strategy of solidifying its core product quality and maintaining market position while providing comprehensive support to clients throughout their development stages [7]. - The company aims to avoid blind pursuit of trends and instead focus on steady innovation to serve the global market effectively [7].